Onzima Ventures PLC Update on Investment

 
TIDMONZ 
 
Onzima Ventures PLC 
 
                          ("Onzima" or the "Company") 
 
  Investee company N4 Pharma announces formation of scientific advisory panel 
 
N4 Pharma Limited ("N4 Pharma"), in which Onzima holds a 49% equity stake, has 
announced that its intellectual property partner OPAL IP has formed a 
scientific advisory panel to provide advice and guidance on N4 Pharma's 
reformulation projects, the first of which is its reformulation of sildenafil. 
 
The panel is made up of Professor Karrar Khan, formerly Head of Pharmaceutical 
Development for Boots Pharmaceuticals and Knoll, Doctor David Templeton, an 
expert in pharmacokinetics and translational science, and Doctor Sean 
McCrossen, an expert in pharmaceutical development. 
 
N4 Pharma CEO Nigel Theobald commented: 
 
"This is a very strong advisory panel which together brings over 90 years' 
experience to our development programs. It will be a huge asset to help make 
sure that our reformulations meet the requirements of industry and the 
regulators and we are delighted that OPAL IP has been able to put together such 
a strong team." 
 
For further information please contact: 
 
Onzima Ventures PLC                                                  Tel:  +44 
(0) 1732 366 561 
Gavin Burnell, Luke Cairns 
 
Nominated Adviser 
Cairn Financial Advisers LLP                                        Tel:  +44 
(0) 20 7148 7900 
Sandy Jamieson, Liam Murray 
 
Broker 
Peterhouse Corporate Finance Limited                           Tel:  +44 (0) 20 
7469 0930 
Guy Miller, Lucy Williams 
 
 
 
END 
 

(END) Dow Jones Newswires

September 06, 2016 05:38 ET (09:38 GMT)